[ad_1]
FRIDAY, Jan. 5, 2024 (HealthDay Information) — People who take Ozempic or Wegovy for diabetes and weight reduction needn’t fear a couple of greater danger of suicidal ideas or emotions whereas on the drugs, a brand new, giant evaluation finds.
Within the examine, which was funded by the U.S. Nationwide Institutes of Well being, researchers turned to a database of greater than 100 million affected person information to measure the dangers of suicidal ideation amongst individuals utilizing semaglutide, which is bought as Ozempic for kind 2 diabetes and Wegovy for weight reduction.
The outcomes have been revealed Jan. 5 within the journal Nature Medication.
Examine creator Dr. Rong Xu, a professor of biomedical informatics at Case Western Reserve College Faculty of Medication in Cleveland, instructed CNN that she determined to look into the difficulty after European regulators opened a probe into semaglutide and reviews of suicidal ideas final summer time.
Simply this week, a quarterly report from the U.S. Meals and Drug Administration revealed that the company is wanting into comparable reviews amongst customers of a number of weight-loss medicine, together with Ozempic and Wegovy.
For the brand new evaluation, Xu and her staff, which included Nationwide Institute on Drug Abuse Director Dr. Nora Volkow, in contrast circumstances of suicidal ideation amongst individuals taking semaglutide with these taking different medicines for weight reduction or diabetes.
“We noticed a decrease incidence of suicidal ideations in sufferers who had taken semaglutide than in sufferers who have been handled with non-GLP1R-targeting drugs for a similar circumstances,” Volkow instructed CNN. The GLP-1 receptor is what semaglutide targets.
The evaluation included greater than 240,000 individuals with weight problems and greater than 1.5 million with kind 2 diabetes. It appeared on the danger of suicidal ideation inside six months of beginning the medicines, in addition to at later occasions.
At six months, it discovered that amongst individuals taking the drug for weight reduction, semaglutide was linked to a 73% decrease danger of first-time suicidal ideation and a 56% decrease danger of recurrent suicidal ideation, CNN reported. The medicine that semaglutide was in comparison with included bupropion, naltrexone, orlistat, topiramate and phentermine.
For individuals with kind 2 diabetes, the reductions have been 64% and 49%, respectively, CNN reported. Right here, the medicine that semaglutide was in comparison with included insulin, metformin and newer lessons of medicines referred to as DPP-4 and SGLT-2 inhibitors.
What precisely prompted the evaluation?
As the usage of Ozempic and Wegovy exploded over the previous few years, Xu mentioned she heard anecdotal reviews of individuals experiencing a discount in addictive behaviors whereas taking the drugs — exhibiting much less curiosity in issues like alcohol or smoking.
“It was sort of like a paradox,” Xu mentioned of the European probe into suicide and the anecdotal reviews of much less addictive behaviors.
With entry to a database that features de-identified digital well being information from 100.8 million individuals in 59 U.S. well being programs, Xu mentioned she determined to investigate the danger.
Ozempic and Wegovy, together with comparable medicine like Mounjaro and Zepbound, are actually being prescribed to thousands and thousands of sufferers. The most typical uncomfortable side effects are gastrointestinal points like nausea, vomiting and constipation, though reviews of extra severe potential uncomfortable side effects, like abdomen paralysis, have emerged.
Each Wegovy and Zepbound have warnings of their U.S. prescribing details about the danger of suicidal conduct and ideation. The prescribing data for an older medication, Saxenda — a part of the identical GLP-1 receptor class — additionally recommends that sufferers be monitored for melancholy or suicidal ideas or conduct, CNN reported.
Volkow additionally pointed to a earlier weight-loss drug, rimonabant, that was withdrawn from the European market in 2008 over issues about suicidal ideas whereas taking the drug. She famous that rimonabant blocks a cannabinoid kind 1 receptor “that, when blocked, can set off detrimental emotional states.”
She added it’s additionally doable that results of abrupt weight reduction might “make some individuals susceptible.”
Regardless that semaglutide was related to a decrease danger of suicidal ideation within the newest examine, Xu and Volkow wrote in a analysis briefing that the info “don’t but justify off-label remedy” for suicidal ideas.
Nonetheless, Volkow famous, “there may be curiosity in testing semaglutide as a possible remedy for melancholy.”
In reality, no less than one trial is now recruiting sufferers for that very objective.
Extra data
Go to Medication.com for extra on weight-loss medicine.
SOURCE: Nature Medication, Jan. 4, 2024; CNN
Copyright © 2024 HealthDay. All rights reserved.
[ad_2]
Source link
